Author | Gary Gize, MD

Articles

Gemcitabine, Paclitaxel, and Trastuzumab in Metastatic Breast Cancer

February 01, 2001

ByKathy D. Miller, MD

Judy Sisk, RN

Rafat Ansari, MD

Gary Gize, MD

Sreenivasa Nattam, MD

Kenneth Pennington, MD

George W. Sledge, Jr, MD

A phase II trial evaluated the effectiveness and toxicity of combination paclitaxel (Taxol), gemcitabine (Gemzar), and trastuzumab (Herceptin) as first-line therapy for patients with newly diagnosed HER2-overexpressing